Ronald A Depinho

US Patent:

6613750, Sep 2, 2003

Filed:

Mar 19, 1998

Appl. No.:

09/044602

Inventors:

Ronald A. DePinho - Pelham Manor NY

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

A01N 4304

US Classification:

514 44, 435455, 424 9321

Abstract:

The present invention provides a novel method of inhibiting the growth of tumor cells based upon the discovery that p19 acts as a suppressor of oncogenic transformation by binding to the MDM2 oncoprotein and blocking MDM2s ability to target associated proteins, such as p53 and Rb, for proteosomal degradation. The method provided by the present invention inhibits the growth of a tumor cell by administering to the cell an effective amount of p19 or a mimetic thereof, and p53 to inhibit the growth of the tumor cell. Also provided by the present invention are pharmaceutical composition comprising p19 or a mimetic thereof, and/or p53.

US Patent:

6639121, Oct 28, 2003

Filed:

Jul 19, 2000

Appl. No.:

09/619247

Inventors:

Ronald A. DePinho - Boston MA
Lynda Chin - Boston MA

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

A01K 67033

US Classification:

800 10, 800 3, 800 8, 800 9, 800 18, 435455, 435325, 4353201

Abstract:

A non-human mammal having incorporated into its genome an expression construct in which nucleic acid encoding an oncogene is operably linked to an inducible promoter; the mammal further has a genetic mutation that causes it to have an increased susceptibility to cancer.

US Patent:

6680371, Jan 20, 2004

Filed:

Aug 3, 2001

Appl. No.:

09/921640

Inventors:

Ronald A. DePinho - Brookline MA

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

C07K 1400

US Classification:

530350, 536 234, 536 235

Abstract:

The present invention provides a novel MHRII-associated protein designated MHRII-AP62 and antibodies immunoreactive with the MHRII-AP62 protein. Also provided are kits containing these antibodies and methods of using the antibodies for the detection of the MHRII-AP62 protein. The present invention also provides for a nucleic acid encoding the MHRII-AP62 protein and nucleic acid probes for use in the detection of the MHRII-AP62 protein. Further provided by the present invention are agents that mimic the activity of the MHRII-AP62 protein by binding to the MHRII, agents that inhibit the activity of the MHRII-AP62 protein by binding to the MHRII-AP62 protein, or by binding to the nucleic acid encoding the MHRII-AP62 protein, and methods of using these agents to treat cancer and cancer causing diseases.

US Patent:

6767719, Jul 27, 2004

Filed:

Mar 16, 1998

Appl. No.:

09/042460

Inventors:

Gregg B. Morin - Palo Alto CA
Richard Allsopp - Mountain View CA
Ronald A. DePinho - Pelham Manor NY
Roger A. Greenberg - Bronx NY

Assignee:

Geron Corporation - Menlo Park CA
Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva University - Bronx NY

International Classification:

C12P 2106

US Classification:

435 691, 4353201, 435325, 435455, 536 231, 536 235, 530350

Abstract:

This invention provides for urine elomerase everse ranscriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.

US Patent:

6897197, May 24, 2005

Filed:

Apr 28, 2003

Appl. No.:

10/424630

Inventors:

Ronald A. DePinho - Pelham Manor NY, US

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

A01N037/18
C07K001/00

US Classification:

514 2, 530350

Abstract:

The present invention provides a novel method of inhibiting the growth of tumor cells based upon the discovery that p19acts as a suppressor of oncogenic transformation by binding to the MDM2 oncoprotein and blocking MDM2's ability to target associated proteins, such as p53 and Rb, for proteosomal degradation. The method provided by the present invention inhibits the growth of a tumor cell by administering to the cell an effective amount of p19or a mimetic thereof, and p53 to inhibit the growth of the tumor cell. Also provided by the present invention are pharmaceutical composition comprising p19or a mimetic thereof, and/or p53.

US Patent:

7371515, May 13, 2008

Filed:

Mar 28, 2002

Appl. No.:

10/112503

Inventors:

Ronald A. Depinho - Brookline MA, US
Lynda Chin - Brookline MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/70
C12N 15/00
C12N 15/63
A01N 63/00

US Classification:

435 5, 4353201, 435455, 424 9321

Abstract:

The invention provides methods and materials for identifying and characterizing genes related to phenotypes such as cancer and cell survivability. Also provided in the invention are cells and transgenic, non-human mammals that can be used in these methods.

US Patent:

7595158, Sep 29, 2009

Filed:

Oct 25, 2005

Appl. No.:

11/259640

Inventors:

Alex Stegh - Boston MA, US
Hyung Gee Kim - Seoul, KR
Ronald A. Depinho - Brookline MA, US
Lynda Chin - Brookline MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6, 435 29, 530350

Abstract:

The invention provides methods and materials related to Bcl2L12 polypeptides and the biological activities of Bcl2L12 polypeptides. For example, the invention provides methods and materials related to identifying activators and inhibitors of Bcl2L12 polypeptide activities such as the ability to block apoptosis and promote cell growth and transformation. The invention also provides methods and materials for treating mammals having cancer.

US Patent:

7622630, Nov 24, 2009

Filed:

Aug 27, 2004

Appl. No.:

10/570116

Inventors:

Joerg Heyer - Cambridge MA, US
Murray Robinson - Boston MA, US
William Rideout, III - Cambridge MA, US
Ronald Depinho - Brookline MA, US
Steven C. Clark - Winchester MA, US
Yinghui Zhou - Belmont MA, US
Tyler Jacks - West Newton MA, US
Ronan C. O'Hagan - Arlington MA, US

Assignee:

AVEO Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12N 15/00
A01K 67/00
C12N 5/06

US Classification:

800 25, 800 10, 800 18, 435354

Abstract:

Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.